|
1.Prisant LM and Mondy JS, Abdominal Aortic Aneurysm. The Journal of Clinical Hypertension, 2004. 6(2): p. 85-89. 2.Gillum RF, Epidemiology of aortic aneurysm in the United States. Journal of Clinical Epidemiology, 1995. 48 (11): p. 1289-1298. 3.Jayr C, et al., Preoperative and intraoperative factors associated with prolonged mechanical ventilation. A study in patients following major abdominal vascular surgery. Chest, 1993. 103(4): p. 1231-1236. 4.El-Hamamsy, et al., Cellular and molecular mechanisms of thoracic aortic aneurysms. Nat Rev Cardiol, 2009. 6(12): p. 771-786. 5.Glagov S, et al., New concepts of the relation of structure to function in the arterial wall. Proc Inst Med Chic, 1968. 27(5): p. 106. 6.Silver F, et al., Relationship between hierarchical structure and mechanical properties of the arteries. Functional abnormalities of the aorta, ed. H. Boudoulas, P. Toutouzas, and C. Wooley. 1996, Armonk (NY): Futura Publishing Company. 7.Narayanan AS, et al., Elastin Synthesis in Arterial Smooth Muscle Cell Culture. The Journal of Cell Biology pages 1976 68(9): p. 411-419 8.Davidson JM, et al., Control of elastin synthesis: molecular and cellular aspects. Regulation of matrix accumulation, ed. R. Mecham. 1986, New York: Academic Press. 177-216. 9.Parks W, et al., Elastin. Adv Molec Cell Biol, 1993. 6: p. 133-182. 10.Linsenmayer TF, Collagen. Cell biology of extracellular matrix ed. E. Hay. 1991, New York: Plenum Press. 11.Procop D, et al., Biosyntseis of collagen and its disorders (part I). N Engl J Med, 1979. 301: p. 13-24. 12.Prockop D, et al., The biosynthesis of collagen and its disorders (part II). N Engl J Med, 1979. 301: p. 77-85. 13.Tilson MJ, J. Elefraides and C. Brophy, Tensile strength and collagen in abdominal aortic aneurysm disease. The cause and management of aneurysms, ed. R. Greenhsalgh, J. Mannick, and J. Powell. 1990, London: Saunders. 97-104. 14.Dorbin PB, Baker WH., Elastolytic and collagenolytic studies of arteries: implications for the mechanical properties of aneurysms. Arch Surg, 1984. 119: p. 405-9. 15.Dorbin PB, et al., Failure of elastin or collagen as possible critical connective tissue alterations underlying aneurysmal dilatation. Cardiovasc Surg, 1994. 2: p. 484-8. 16.Powell JT., A textbook for vascular surgeons. Mechanisms of vascular disease, ed. R. Fitridge and M.M. Thompson. 2007, Cambridge: Cambridge university press. 226-234. 17.Shah PK., Inflammation, Metalloproteinases, and Increased Proteolysis : An Emerging Pathophysiological Paradigm in Aortic Aneurysm. Circulation Research, 1997. 96(7): p. 2115-2117. 18.Herron GS, et al., Connective tissue proteinases and inhibitors in abdominal aortic aneurysms. Involvement of the vasa vasorum in the pathogenesis of aortic aneurysms. Arteriosclerosis, Thrombosis, and Vascular Biology, 1991. 11(6): p. 1667-1677. 19.Holmes DR, et al., Medial neovascularization in abdominal aortic aneurysms: A histopathologic marker of aneurysmal degeneration with pathophysiologic implications. Journal of Vascular Surgery, 1995. 21(5): p. 761-772. 20.MacSweeney STR, PoweL JT, Pathogenesis of abdominal aortic aneurysm. British Journal of Surgery, 1994. 81(7): p. 935-941. 21.Abraham M, et al., The role of IL-18 and IL-12 in the modulation of matrix metalloproteinases and their tissue inhibitors in monocytic cells. . Int Immunol, 2002. 14: p. 1449-57. 22.Christopher P. Cheng, David Parker, and CA Taylor, Quantification of Wall Shear Stress in Large Blood Vessels Using Lagrangian Interpolation Functions with Cine Phase-Contrast Magnetic Resonance Imaging. Annals of Biomedical Engineering, 2002. 30: p. 1020–1032. 23.Vardulaki KA, et al., Quantifying the risks of hypertension, age, sex and smoking in patients with abdominal aortic aneurysm. British Journal of Surgery, 2000. 87(2): p. 195-200. 24.Brown LC, et al., Risk Factors for Aneurysm Rupture in Patients Kept Under Ultrasound Surveillance. Annals of Surgery, 1999. 230(3): p. 289. 25.Kuivaniemi H, et al., Familial abdominal aortic aneurysms: Collection of 233 multiplex families. Journal of Vascular Surgery, 2003. 37(2): p. 340-345. 26.Pleumeekers HJ, et al., Aneurysms of the Abdominal Aorta in Older Adults. American Journal of Epidemiology, 1995. 142(12): p. 1291-1299. 27.Castleden WM, et al., Abdominal aortic aneurysms in Western Australia: Descriptive epidemiology and patterns of rupture. British Journal of Surgery, 1985. 72(2): p. 109-112. 28.Reed W, et al., , Learning From the Last Ultrasound: A PopulationBased Study of Patients With Abdominal Aortic Aneurysm. Arch Intern Med, 1997. 157(18): p. 2064-2068. 29.McFarlane MJ, The Epidemiologic Necropsy for Abdominal Aortic Aneurysm. The Journal of the American Medical Association, 1991. 256(16): p. 2085-2088. 30.Lederle FA, et al., Prevalence and Associations of Abdominal Aortic Aneurysm Detected through Screening. Annals of Internal Medicine, 1997. 126(6): p. 441-449. 31.Shimizu K, Mitchell RN, and Libby P, Inflammation and cellular immune responses in abdominalaorticaneurysms. Arterioscler Thromb Vasc Biol, 2006. 26(5): p. 987-994. 32.Menashi S, et al., Collagen in abdominalaorticaneurysm: typing, content, and degradation. J Vasc Surg, 1987. 6(6): p. 578-582. 33.Lopez-Candales A, et al., Decreased vascular smooth muscle cell density in medial degeneration of human abdominalaorticaneurysms. Am J Pathol, 1997. 150(3): p. 993-1007. 34.Choke E, et al., Abdominalaorticaneurysm rupture is associated with increased medial neovascularization and overexpression of proangiogenic cytokines. Arterioscler Thromb Vasc Biol, 2006. 26(9): p. 2077-82. 35.Campa JS, Greenhalgh RM, Elastin degradation in abdominal aortic aneurysms. Atherosclerosis, 1987. 65(1–2): p. 13-21. 36.Vine NP, et al., Metalloproteinases in degenerative aortic disease. Clin Sci, 1991. 81: p. 233-9. 37.Thompson RW, et al., Role of matrix metalloproteinases in abdominal aortic aneurysms. Ann NY Acad Sci, 1996. 800: p. 157-74. 38.Knox JB, et al., Evidence for Altered Balance Between Matrix Metalloproteinases and Their Inhibitors in Human Aortic Diseases Circulation Research, 1997. 95: p. 205-212. 39.Newman KM, et al., Identification of matrix metalloproteinases 3 (stromelysin-1) and 9 (gelatinase B) in abdominal aortic aneurysm. Arterioscler Thromb Vasc Biol, 1994. 14: p. 1315-1320. 40.Curci JA, et al., Expression and localization of macrophage elastase (matrix metalloproteinase-12) in abdominal aortic aneurysms. J Clin Invest, 1998. 102: p. 1900-1910. 41.Mao D, et al., Expression of collagenase-3 (MMP-13) in human abdominal aortic aneurysms and vascular smooth muscle cells in culture. Biochem Biophys Res Commun, 1999. 261: p. 904-910. 42.Schneiderman J, et al., Expression of fibrinolytic genes in atherosclerotic abdominal aortic aneurysm wall. A possible mechanism for aneurysm expansion. J Clin Invest, 1995. 96: p. 639-645. 43.Reilly JM, Sicard GA, Abnormal expression of plasminogen activators in aortic aneurysmal and occlusive disease. J Vasc Surg, 1994. 19: p. 865-872. 44.Jean-Claude J, et al., Possible key for plasmin in the pathogenesis of abdominal aortic aneurysms. . Surgery, 1994. 116: p. 472-478. 45.Sukhova GK, et al., J Clin Invest, 1998. 102: p. 576-583. 46.Keeling WB, et al., An overview of matrix metalloproteinases in the pathogenesis and treatment of abdominal aortic aneurysms. Vascular and Endovascular Surgery, 2005. 39: p. 457-464. 47.McMillan WD, et al., Size matters: the relationship between MMP-9 expression and aortic diameter. Circulation Research, 1997. 96: p. 2228-2232. 48.McMillan WD, et al., Increased plasma levels of metalloproteinase-9 are associated with abdominal aortic aneurysms. J Vasc Surg, 1999. 29: p. 122-7. 49.Hovsepian DM, et al., Elevated plasma levels of matrix metalloproteinase-9 (MMP-9) in patients with abdominal aortic aneurysms: a circulating marker of degenerative aneurysm disease. J Vasc Intervent Radiol, 2000. 11: p. 1345-52. 50.Pyo R, et al., Targeted gene disruption of matrix metalloproteinase-9 (gelatinase B) suppresses development of experimental abdominal aortic aneurysms. J Clin Invest, 2000. 105: p. 1641-1649. 51.Carmeliet P, et al., Urokinase-generated plasmin activates matrix metalloproteinases during aneurysm formation. Nat Genet, 1997. 17(4): p. 439-444. 52.Banyai L, Tordai H., The gelatin-binding site of human 72 kDa type IV collagenase (gelatinase A). Biochem J. , 1994 298((Pt 2)): p. 403-7. 53.Overall CM, Wrana JL., Transcriptional and post-transcriptional regulation of 72-kDa gelatinase/type IV collagenase by transforming growth factor-beta 1 in human fibroblasts. Comparisons with collagenase and tissue inhibitor of matrix metalloproteinase gene expression. J Biol Chem, 1991. 266(21): p. 14064-71. 54.Brown PD, et al., Independent expression and cellular processing of Mr 72,000 type IV collagenase and interstitial collagenase in human tumorigenic cell lines. Cancer Res, 1990. 50(19): p. 6184-91. 55.Collier IE, et al., H-ras oncogene-transformed human bronchial epithelial cells (TBE-1) secrete a single metalloprotease capable of degrading basement membrane collagen. J Biol Chem, 1988. 263(14): p. 6579-87. 56.Overall CM, et al., Concanavalin A produces a matrix-degradative phenotype in human fibroblasts. Induction and endogenous activation of collagenase, 72-kDa gelatinase, and Pump-1 is accompanied by the suppression of the tissue inhibitor of matrix metalloproteinases. J Biol Chem, 1990. 265(34): p. 21141-51. 57.Matrisian LM., Matrix metalloproteinase gene expression. Ann N Y Acad Sci, 1994. 732: p. 42-50. 58.Tomita T, et al., Granulocyte-macrophage colonystimulating factor upregulates matrix metalloproteinase-2 (MMP-2) and membrane type-1 MMP (MT1-MMP) in human head and neck cancer cells. Cancer Lett, 2000. 156: p. 83-91. 59.Sugimoto C, et al., Granulocyte colony-stimulating factor (G-CSF)-mediated signaling regulates type IV collagenase activity in head and neck cancer cells. Int J Cancer, 2001. 93: p. 42-6. 60.Cipollone F, et al., Overexpression of functionally coupled cyclooxygenase-2 and prostaglandin E synthase in symptomatic atherosclerotic plaques as a basis of prostaglandin E(2)-dependent plaque instability. . Circulation Research, 2001. 104: p. 921-7. 61.Kleiner D E, et al., Stability analysis of latent and active 72-kDa type IV collagenase: the role of tissue inhibitor of metalloproteinase -2 (TIMP-2). Biochemistry, 1993. 32: p. 1583-1592. 62.Ginestra A, et al., Urokinase plasminogen activator and gelatinases are associated with membrane vesicles shed by human HT1080 fibrosarcoma cells. J Biol Chem, 1997. 272: p. 17216-17222. 63.Mazzieri R, et al., Control of type IV collagenase activity by components of the urokinase-plasmin system: A regulatory mechanism with cell-bound reactants. EMBO J., 1997. 16: p. 2319-2332. 64.Zucker S et al., Thrombin induces the activation of progelatinase A in vascular endothelial cells. Physiologic regulation of angiogenesis. J Biol Chem, 1995. 270: p. 23730-23738. 65.Rajagopalan S, et al., Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation.Contribution to alterations of vasomotor tone. J Clin Invest., 1996. 97: p. 1916-23. 66.Philip S and Bulbule A., Osteopontin stimulates tumor growth and activation of promatrix metalloproteinase-2 through nuclear factor-kappa Bmediated induction of membrane type 1 matrix metalloproteinase in murine melanoma cells. . J Biol Chem, 2001. 276: p. 44926-35. 67.Philip S, et al., Osteopontin induces nuclear factor kappa B-mediated promatrix metalloproteinase-2 activation through I kappa B alpha /IKK signaling pathways, and curcumin (diferulolylmethane) down-regulates these pathways. J Biol Chem, 2003. 278: p. 14487-97. 68.Bruemmer D, et al., Angiotensin II-accelerated atherosclerosis and aneurysm formation is attenuated in osteopontin-deficient mice. . J Clin Invest., 2003. 112: p. 1318-31. 69.Arenas IA, et al., Angiotensin II-induced MMP-2 release from endothelial cells is mediated by TNF-alpha. Am J Physiol Cell Physiol. , 2004. 286: p. 779-84. 70.Wilhelm SM, et al., SV40-transformed human fibroblasts secrete a 92-kDa type-IV collagenase which is identical to that secreted by normal human macrophages. J Biol Chem, 1989. 264: p. 17213-17221. 71.Van Wart HE, et al., Cysteine switch: A pronciple of regulation of metalloproteinase activity with potential applicability to entire matrix metalloproteinase family. Proc. Natl. Acad. Sci. USA, 1990. 87(14): p. 5578-5582. 72.Reilly JM, Brophy CM., Characterization of an elastase from aneurysmal aorta which degrades intact aortic elastin. Ann Vasc Surg., 1992. 6: p. 499-502. 73.Newman KM and Jean-Claude J., Cellular localization of matrix metalloproteinases in the abdominal aortic aneurysm wall. . J Vasc Surg, 1994. 20: p. 814-20. 74.Newman KM and Ogata Y., Malon AM, Identification of matrix metalloproteinases3 (stromelysin-1) and 9 (gelatinase B) in abdominal aortic aneurysm. Arterioscler Thromb 1994. 14: p. 1315-20. 75.McMillan WD, et al., In situ localization and quantification of mRNA for 92-kD type IV collagenase and its inhibitor in aneurysmal, occlusive, and normal aorta. Arterioscler Thromb Vasc Biol., 1995. 15: p. 1139-44. 76.Welgus HG, Campbell EJ, and Cury JD., Neutral metalloproteinases produced by human mononuclear phagocytes: enzyme profile, regulation, and expression during cellular development. J Clin Invest, 1990. 86: p. 1496-502. 77.Thompson RW, Holmes DR, and Mertens RA, Production and localization of 92-kilodalton gelatinase in abdominal aortic aneurysms: an elastolytic metalloproteinase expressed by aneurysm-infiltrating macrophages. J Clin Invest, 1995. 96: p. 318-26. 78.Gum R, et al., Stimulation of 92-kDa gelatinase B promoter activity by ras is mitogen-activated protein kinase kinase 1-independent and requires multiple transcription factor binding sites including closely spaced PEA3/ets and AP-1 sequences. J Biol Chem, 1996. 271(18): p. 10672-80. 79.Huhtala P, et al., Complete structure of the human gene for 92-kDa type IV collagenase. Divergent regulation of expression for the 92- and 72-kilodalton enzyme genes in HT-1080 cells. J Biol Chem. , 1991. 266(25): p. 16485-90. 80.Mercurio F et al., Multiple signals converging on NF-kappaB. Curr Opin Cell Biol., 1999. 11(2): p. 226-32. 81.St-Pierre Y, Couillard J and C. Van Themsche, Regulation of MMP-9 gene expression for the development of novel molecular targets against cancer and inflammatory diseases. Expert Opinion on Therapeutic Targets, 2004. 8(5): p. 473-489. 82.Fähling M, et al., Role of nucleolin in posttranscriptional control of MMP-9 expression. Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression, 2005. 1731(1): p. 32-40. 83.Overall CM and Wrana JL., Transcriptional and post-transcriptional regulation of 72-kDa gelatinase/type IV collagenase by transforming growth factor-beta 1 in human fibroblasts. Comparisons with collagenase and tissue inhibitor of matrix metalloproteinase gene expression. J Biol Chem., 1991. 266: p. 14064–14071. 84.Hsu JC, Bravo R, and T. R., Interactions among LRF-1, JunB, c-Jun, and c-Fos define a regulatory program in the G1 phase of liver regeneration. Mol Cell Biol., 1992. 12: p. 4654-4665. 85.Ogata Y, Enghild JJ., Matrix metalloproteinase 3 (stromelysin) activates the precursor for the human matrix metalloproteinase 9. J Biol Chem, 1992. 267(6): p. 3581-4. 86.Okada Y, et al., Matrix metalloproteinase 9 (92-kDa gelatinase/type IV collagenase) from HT 1080 human fibrosarcoma cells. Purification and activation of the precursor and enzymic properties. J Biol Chem, 1992. 267(30): p. 21712-9. 87.Ramos-DeSimone N, et al., Activation of matrix metalloproteinase-9 (MMP-9) via a converging plasmin/stromelysin-1 cascade enhances tumor cell invasion. J Biol Chem., 1999 274(19): p. 13066-76. 88.Fang KC, et al., Dog mastocytoma cells secrete a 92-kD gelatinase activated extracellularly by mast cell chymase. J Clin Invest, 1996. 97(7): p. 1589-96. 89.Fridman R, et al., Activation of progelatinase B (MMP-9) by gelatinase A (MMP-2). Cancer Res., 1995 55(12): p. 2548-55. 90.Sang QX and Birkedal-Hansen H., Proteolytic and non-proteolytic activation of human neutrophil progelatinase B. Biochim Biophys Acta, 1995. 1251(2): p. 99-108. 91.Okamoto T, et al., Activation of matrix metalloproteinases by peroxynitrite-induced protein S-glutathiolation via disulfide S-oxide formation. J Biol Chem, 2001. 276(31): p. 29596-602. 92.Bannikov GA et al., Substrate binding of gelatinase B induces its enzymatic activity in the presence of intact propeptide. J Biol Chem, 2002. 277(18): p. 16022-7. 93.Gomez DE, et al., Tissue inhibitors of metalloproteinases: structure, regulation and biological functions. Eur J Cell Biol., 1997. 74(2): p. 111-22. 94.Brew K and Dinakarpandian D., Tissue inhibitors of metalloproteinases: evolution, structure and function. . Biochim Biophys Acta., 2000. 1477: p. 267–283. 95.Murphy G, et al., The N-terminal domain of tissue inhibitor of metalloproteinases retains metalloproteinase inhibitory activity. Biochemistry., 1991. 30: p. 8097–8102. 96.Hanemaaijer R, et al., Regulation of matrix metalloproteinase expression in human vein and microvascular endothelial cells: effects of tumor necrosis factor α, interleukin 1 and phorbol ester. Biochem J., 1993. 296: p. 803-809. 97.Galis ZS, et al., Cytokine-stimulated human vascular smooth muscle cells synthesize a complement of enzymes required for extracellular matrix digestion. Circulation Research, 1994. 75: p. 181-189. 98.GalisZS, et al., Matrix Metalloproteinases in Vascular Remodeling and Atherogenesis. Circulation Research, 2002. 90(3): p. 251-262. 99.Steteler-Stevenson and WG, Krutzsch HC., Tissue inhibitor of metalloproteinase-2 (TIMP-2). . J Biol Chem, 1989. 264: p. 17374–17378. 100.Kinoshita T, et al., TIMP-2 promotes activation of progelatinase A by membrane-type 1 matrix metalloproteinase immobilized on agarose beads. J Biol Chem 1998. 273: p. 16098–16103. 101.Kurschat P, et al., Tissue inhibitor of matrix metalloproteinase-2 regulated matrix metalloproteinase-2 activation. . J Biol Chem, 1999. 274: p. 21056–21062. 102.Hutton M, et al., Kinetic analysis of the mechanism of interaction of full-length TIMP-2 and gelatinase A: evidence for the existence of a low-affinity intermediate. . Biochemistry., 1998. 37: p. 10094-8. 103.Tamarina NA, et al., Expression of matrix metalloproteinases and their inhibitors in aneurysms and normal aorta. Surgery, 1997. 122: p. 264-72. 104.Kengo Nishimura, Shigetsugu Ohgi, and E. Nanba., Expression of MMP-2, MMP-9 and TIMP-1 in the Wall of Abdominal Aortic Aneurysms. Yonago Acta medica 2001. 44: p. 25–35. 105.McMIllan WD, et al., Incraesed plasma levels of metalloproteinase-9 are associated with abdominal aortic aneurysms. J Vasc Surg, 1999. 29: p. 122-7. 106.Nakamura M, et al., Circulating biochemical marker levels of collagen metabolism are abnormal in patients with abdominal aortic aneurysm. Angiology, 2000. 51: p. 385-92. 107.Lopez-Candales A, et al., Decreased vascular smooth muscle cell density in medial degeneration of human abdominal aortic aneurysms. Am. J. Pathol. , 1997. 150: p. 993-1007. 108.Lopez-Candales A, et al., Decreased vascular smooth muscle cell density in medial degeneration of human abdominal aortic aneurysms. . Am J Pathol., 1997. 150: p. 993-1007. 109.Henderson EL, et al., Death of smooth muscle cells and expression of mediators of apoptosis by T lymphocytes in human abdominal aortic aneurysms. Circulation. , 1999. 99: p. 96-104. 110.Walton LJ, et al., Inhibition of prostaglandin E2 synthesis in abdominal aortic aneurysms: implications for smooth muscle cell viability, inflammatory processes, and the expansion of abdominal aortic aneurysms. Circulation Research, 1999. 100: p. 48-54. 111.Eliason JL, et al., Neutrophil depletion inhibits experimental abdominal aortic aneurysm formation. . Circulation., 2005. 112: p. 232-240. 112.Sun J, et al., Mast cells modulate the pathogenesis of elastase-induced abdominal aortic aneurysms in mice. J Clin Invest., 2007. 117: p. 3359–3368. 113.Kaschina E et al., Telmisartan prevents aneurysm progression in the rat by inhibiting proteolysis, apoptosis and inflammation. J Hypertens., 2008. 26: p. 2361–2373. 114.Wang YX, et al., A Rho-kinase inhibitor, attenuates angiotensin II-induced abdominal aortic aneurysm in apolipoprotein E-deficient mice by inhibiting apoptosis and proteolysis. Circulation Research, 2005. 111: p. 2219-2226. 115.Allaire E, et al., Vascular smooth muscle cell endovascular therapy stabilizes already developed aneurysms in a model of aortic injury elicited by inflammation and proteolysis. Ann Surg., 2004. 239(3): p. 417-27. 116.Dai Yamanouchi, et al., Effects of Caspase Inhibitor on Angiotensin II-Induced Abdominal Aortic Aneurysm in Apolipoprotein E-deficient mice. Arteriosclerosis, Thrombosis, and Vascular Biology., 2010. 30: p. 702-707. 117.Zaragoza C, et al., Animal Models of Cardiovascular Diseases. Journal of Biomedicine and Biotechnology, 2011. 2011:497841. Epub 2011 Feb 16. 118.Saraff K, et al., Aortic dissection precedes formation of aneurysms and atherosclerosis in angiotensin II-infused, apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol., 2003. 23: p. 1621-6. 119.Molácek J, et al., Optimization of the model of abdominal aortic aneurysm--experiment in an animal model. J Vasc Res., 2009. 46(1): p. 1-5. 120.Valerie Davis, et al., Matrix Metalloproteinase-2 Production and Its Binding to the Matrix Are Increased in Abdominal Aortic Aneurysms. Arterioscler Thromb Vasc Biol 1998. 18: p. 1625-1633. 121.Caroline Cheng, et al., Atherosclerotic Lesion Size and Vulnerability Are Determined by Patterns of Fluid Shear Stress. Circulation, 2006. 113: p. 2744-2753. 122.Femke A. M. V. I. Hellenthal, et al., Biomarkers of AAA progression. Part 1: extracellular matrix degeneration. Nature Reviews Cardiology, 2009. 6: p. 464-474. 123.Sakalihasan N, et al., Activated forms of MMP2 and MMP9 in abdominal aortic aneurysms. Journal of Vascular Surgery, 1996. 24(1): p. 127-133. 124.Freestone T, et al., Inflammation and matrix metalloproteinases in the enlarging abdominal aortic aneurysm. Arterioscler Thromb Vasc Biol., 1995. 15(8): p. 1145-51. 125.Petersen E, et al., Activity of matrix metalloproteinase-2 and -9 in abdominal aortic aneurysms. Relation to size and rupture. Eur J Vasc Endovasc Surg., 2000. 20(5): p. 457-61. 126.Crowther M, et al., Localization of matrix metalloproteinase 2 within the aneurysmal and normal aortic wall. British Journal of Surgery, 2000. 87(10): p. 1391-1400. 127.Liapis CD, et al., The pivotal role of matrix metalloproteinases in the development of human abdominal aortic aneurysms. Vasc Med. , 2003. 8(4): p. 267-71. 128.Crowther M, et al., Increased matrix metalloproteinase 2 expression in vascular smooth muscle cells cultured from abdominal aortic aneurysms. J Vasc Surg. , 2000. 32(3): p. 575-83. 129.Rafael Fridman, et al., Cell surface association of matrix metalloproteinase-9 (gelatinase B). Cancer and Metastasis Reviews, 2003. 22: p. 153-166.
|